Advertisement

Reactions Weekly

, Volume 1744, Issue 1, pp 69–69 | Cite as

Bosutinib/imatinib/ibrutinib

Pulmonary aspergillosis: 3 case reports
Case report
  • 6 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series, three patients (two women and one man) aged 58−72 years were described, who developed invasive pulmonary aspergillosis during treatment with ibrutinib, imatinib or bosutinib [routes not stated].

A 63-year-old woman developed invasive pulmonary aspergillosis secondary to Aspergillus fumigatus during treatment with ibrutinib for chronic B-cell lymphocytic leukaemia (CLL). She started receiving treatment with ibrutinib 420mg once a day for CLL. She had received chemotherapy prior to the initiation of ibrutinib. Prior to the initiation of ibrutinib, she had received ofatumumab for 4 months, which she discontinued because of increase in white cell count due to an unknown aetiology. On day +10 of ibrutinib therapy, she presented with cough productive of yellow...

Reference

  1. Nasir T, et al. Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors. BMJ Case Reports 12: No. 1, 29 Jan 2019. Available from: URL: http://doi.org/10.1136/bcr-2018-226121 - United Kingdom

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations